Bionik Laboratories Company Management Evaluation
Bionik Laboratories employs about 12 people. The company is managed by 6 executives with a total tenure of roughly 11 years, averaging almost 1.0 years of service per executive, having 2.0 employees per reported executive. Inspection of Bionik Laboratories' management performance can provide insight into the company performance.
| CPA Russo Insider CEO Pres |
| Michal Prywata Director Co-Founder, COO and Director |
Bionik |
Bionik Laboratories Management Team Effectiveness
The company has return on total asset (ROA) of (0.6375) % which means that it has lost $0.6375 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.8325) %, meaning that it created substantial loss on money invested by shareholders. Bionik Laboratories' management efficiency ratios could be used to measure how well Bionik Laboratories manages its routine affairs as well as how well it operates its assets and liabilities.Bionik Laboratories Workforce Comparison
Bionik Laboratories Corp is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 109. Bionik Laboratories retains roughly 12.0 in number of employees claiming about 11% of equities under Health Care industry.
Bionik Laboratories Corp Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Bionik Laboratories Corp Price Series Summation is a cross summation of Bionik Laboratories price series and its benchmark/peer.
Bionik Laboratories Notable Stakeholders
A Bionik Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bionik Laboratories often face trade-offs trying to please all of them. Bionik Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bionik Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michal Prywata | Co-Founder, COO and Director | Profile | |
| CPA Russo | CEO Pres | Profile | |
| Mark Eiseman | Sales Director | Profile | |
| Daniel CPA | Ex CFO | Profile | |
| Dan CPA | Ex CFO | Profile | |
| John Smathers | Director Operations | Profile |
About Bionik Laboratories Management Performance
The success or failure of an entity such as Bionik Laboratories Corp often depends on how effective the management is. Bionik Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bionik management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bionik management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts. BIONIK LABORATORIES operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange. It employs 12 people.
Bionik Laboratories Workforce Analysis
Traditionally, organizations such as Bionik Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bionik Laboratories within its industry.Bionik Laboratories Manpower Efficiency
Return on Bionik Laboratories Manpower
| Revenue Per Employee | 106.1K | |
| Revenue Per Executive | 212.3K | |
| Net Loss Per Employee | 867.3K | |
| Net Loss Per Executive | 1.7M | |
| Working Capital Per Employee | 74.2K | |
| Working Capital Per Executive | 148.5K |
Other Information on Investing in Bionik Pink Sheet
Bionik Laboratories financial ratios help investors to determine whether Bionik Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bionik with respect to the benefits of owning Bionik Laboratories security.